Donald Bellgrau
Fondateur chez ApopLogic Pharmaceuticals, Inc.
Profil
Donald Bellgrau is the founder of GlobeImmune, Inc. (founded in 1995) and ApopLogic Pharmaceuticals, Inc. (founded in 2006).
At ApopLogic Pharmaceuticals, Inc., he holds the title of Director & Founding Scientist.
Currently, Dr. Bellgrau is a Professor at The University of Colorado.
In the past, he worked as a Member-Scientific Staff at the Basel Institute for Immunology.
He obtained his doctorate degree from the University of Pennsylvania.
Postes actifs de Donald Bellgrau
| Sociétés | Poste | Début |
|---|---|---|
| The University of Colorado | Corporate Officer/Principal | 14/09/2009 |
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Fondateur | 01/01/2006 |
Anciens postes connus de Donald Bellgrau
| Sociétés | Poste | Fin |
|---|---|---|
| GLOBEIMMUNE, INC. | Fondateur | - |
| Basel Institute for Immunology | Corporate Officer/Principal | - |
Formation de Donald Bellgrau
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GLOBEIMMUNE, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |